Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria

Clinical Microbiology Reviews

Volumn 25, Issue 3, 2012, Pages 545-582

  Brown Elliott, Barbara A ^a   Nash, Kevin A ^b   Wallace, Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM; CEFOXITIN; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ETHAMBUTOL; GAMMA INTERFERON; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; INTERLEUKIN 12 RECEPTOR; ISONIAZID; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; SULFONAMIDE; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGAR DIFFUSION; ALLERGIC PNEUMONITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ATYPICAL MYCOBACTERIOSIS; BACTEREMIA; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIUM ISOLATE; BONE INFECTION; BRONCHIECTASIS; BROTH DILUTION; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CYSTIC FIBROSIS; DISK DIFFUSION; DNA REPLICATION; EPSILOMETER TEST; EYE INFECTION; FOLATE METABOLISM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS ARTHRITIS; LABORATORY TEST; LYMPHADENITIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM IMMUNOGENUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM MUCOGENICUM; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM TERRAE; MYCOBACTERIUM XENOPEI; NATURAL KILLER CELL; NONHUMAN; NUCLEIC ACID SYNTHESIS; NUCLEOTIDE SEQUENCE; OTITIS MEDIA; PROSTHESIS INFECTION; PROTEIN SYNTHESIS; RESPIRATORY TRACT INFECTION; REVIEW; RNA SYNTHESIS; SEROTYPE; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL PATIENT; T LYMPHOCYTE; WOUND INFECTION;

CORYNEBACTERINEAE;

EID: 84864508047     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.05030-11     Document Type: Review

References (464)

1. Adékambi T, et al. 2004. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J. Clin. Microbiol. 42:5493-5501.
2. Ahn CH, Wallace RJ, Jr, Steele LC, Murphy DT. 1987. Sulfonamidecontaining regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am. Rev. Respir. Dis. 135: 10-16.
3. Ainsa JA, et al. 1998. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J. Bacteriol. 180: 5836-5843.
4. Aínsa JA, Martin C, Gicquel B, Gomez-Luis R. 1996. Characterization of the chromosomal aminoglycoside 2=-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrob. Agents Chemother. 40: 2350-2355.
5. Ainsa JA, et al. 1997. Aminoglycoside 2=-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2=)-Ic gene from Mycobacterium tuberculosis and the aac(2=)-Id gene from Mycobacterium smegmatis. Mol. Microbiol. 24: 431-441.
6. Aksamit TR. 2003. Hot tub lung: infection, inflammation, or both? Semin. Respir. Infect. 18: 33-39.
7. Al-Rubeai M, Dale JW. 1986. Purification and characterization of dihydrofolate reductase from Mycobacterium phlei. Biochem. J. 235: 301-303.
8. Alcaide F, Pfyffer GE, Telenti A. 1997. Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob. Agents Chemother. 41: 2270-2273.
9. Andersen SJ, Quan S, Gowan B, Dabbs ER. 1997. Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic. Antimicrob. Agents Chemother. 41: 218-221.
10. Andini N, Nash KA. 2006. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob. Agents Chemother. 50: 2560-2562.
11. Anokhina MM, Barta A, Nierhaus KH, Spiridonova VA, Kopylov AM. 2004. Mapping of the second tetracycline binding site on the ribosomal small subunit of E. coli. Nucleic Acids Res. 32: 2594-2597.
12. Argyrou A, Jin L, Siconilfi-Baez L, Angeletti RH, Blanchard JS. 2006. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 45: 13947-13953.
13. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol. 13: 408-413.
14. Arias CA, et al. 2008. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J. Clin. Microbiol. 46: 892-896.
15. Austin WK, Lockey MW. 1976. Mycobacterium fortuitum mastoiditis. Arch. Otolaryngol. 102: 558-560.
16. Babady NE, et al. 2010. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO sensititre panels and JustOne strips. J. Clin. Microbiol. 48: 1749-1752.
17. Bag S, Tawari NR, Degani MS, Queener SF. 2010. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens. Bioorg. Med. Chem. 18: 3187-3197.
18. Bailey M, Chettiath T, Mankin AS. 2008. Induction of erm(C) expression by noninducing antibiotics. Antimicrob. Agents Chemother. 52: 866-874.
19. Band JD, et al. 1982. Peritonitis due to a Mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis. J. Infect. Dis. 145: 9-17.
20. Banerjee A, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
21. Bang D, et al. 2008. Mycobacterium arosiense sp. nov., a slowly growing, soctochromogenic species causing osteomyelitis in an immunocompromised child. Int. J. Syst. Evol. Microbiol. 58: 2398-2402.
22. Bange F-C, Brown BA, Smaczny C, Wallace RJ, Jr, Böttger EC. 2001. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin. Infect. Dis. 32: 1648-1650.
23. Bange F-C, Kirschner P, Böttger EC. 1999. Recovery of mycobacteria from patients with cystic fibrosis. J. Clin. Microbiol. 37: 3761-3763.
24. Barrett OJ, Pushechnikov A, Wu M, Disney MD. 2008. Studying aminoglycoside modification by the acetyltransferase class of resistancecausing enzymes via microarray. Carbohydr. Res. 343: 2924-2931.
25. Barrow EW, Suling WJ, Seitz LE, Reynolds RC, Barrow WW. 2006. New antifolate inhibitors for Mycobacterium avium. Med. Chem. 2: 505-510.
26. Bastian S, et al. 2011. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob. Agents Chemother. 55: 775-781.
27. Basu D, Narayankumar DV, Van Beeumen J, Basu J. 1997. Characterization of a beta-lactamase from Mycobacterium smegmatis SN2. Biochem. Mol. Biol. Int. 43: 557-562.
28. Bauer G, Berens C, Projan SJ, Hillen W. 2004. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2_ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53: 592-599.
29. Baysarowich J, et al. 2008. Rifamycin antibiotic resistance by ADPribosylation: structure and diversity of Arr. Proc. Natl. Acad. Sci. U. S. A. 105: 4886-4891.
30. Beckler DR, Elwasila S, Ghobrial G, Valentine JF, Naser SA. 2008. Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. World J. Gastroenterol. 14: 2723-2730.
31. Behr MA, Falinkham JO III. 2009. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol. 4: 1009-1020.
32. Belanger AE, et al. 1996. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. U. S. A. 93: 11919-11924.
33. Bellinzoni M, et al. 2009. Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator. J. Bacteriol. 191: 7531-7537.
34. Bergeron J, et al. 1996. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)-and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40: 2226-2228.
35. Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52: 1570-1572.
36. Biehle JR, Cavalieri SJ, Saubolle MA, Getsinger LJ. 1995. Evaluation ofEtest for susceptibility testing of rapidly growing mycobacteria. J. Clin. Microbiol. 33: 1760-1764.
37. Billinger ME, et al. 2009. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg. Infect. Dis. 15: 1562-1569.
38. Bock RA, Soulages JL, Barrow WW. 2007. Substrate and inhibitor specificity of Mycobacterium avium dihydrofolate reductase. FEBS J. 274: 3286-3298.
39. Bogdan C, et al. 1997. Systemic infection with Mycobacterium genavense following immunosuppressive therapy in a patient who was seronegative for human immunodeficiency virus. Clin. Infect. Dis. 24: 1245-1247.
40. Bolon MK. 2009. The newer fluoroquinolones. Infect. Dis. Clin. North Am. 23: 1027-1051.
41. Bongiorno D, et al. 2010. DNA methylase modifications and other linezolid resistance mutations in coagulase-negative staphylococci in Italy. J. Antimicrob. Chemother. 65: 2336-2340.
42. Bonnefoy A, Girard AM, Agouridas C, Chantot JF. 1997. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother. 40: 85-90.
43. Böttger EC. 1994. Mycobacterium genavense: an emerging pathogen. Eur. J. Clin. Microbiol. Infect. Dis. 13: 932-936.
44. Böttger EC. 1994. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol. 2: 416-421.
45. Böttger EC, et al. 1992. Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet 340: 76-80.
46. Bozdogan B, Appelbaum PC. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23: 113-119.
47. Brodersen DE, et al. 2000. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103: 1143-1154.
48. Brown BA, et al. 1999. Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy. Int. J. Syst. Bacteriol. 49: 1493-1511.
49. Brown BA, Wallace RJ, Jr, Onyi GO. 1992. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob. Agents Chemother. 36: 1987-1990.
50. Brown BA, Wallace RJ, Jr, Onyi GO. 1996. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 40: 874-878.
51. Brown BA, Wallace RJ, Jr, Onyi G, DeRosas V, Wallace RJ III. 1992. Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonaelike organisms. Antimicrob. Agents Chemother. 36: 180-184.
52. Brown-Elliott BA, Bridge Mann L, Hail D, Whitney C, Wallace RJ, Jr. 22 February 2012, posting date. Molecular taxonomy and antimicrobial susceptibility of nontuberculous mycobacteria from eye infections. Cornea [Epub ahead of print.] doi:10.1097/ICO.0b013e31823f8bb9.
53. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ, Jr. 2003. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob. Agents Chemother. 47: 1736-1738.
54. Brown-Elliott BA, Wallace, RJ, Jr. 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin. Microbiol. Rev. 15: 716-746.
55. Brown-Elliott BA, Wallace RJ, Jr, Blinkhorn R, Crist CJ, Mann LM. 2001. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Dis. 33: 1433-1434.
56. Brown-Elliott BA, Wallace RJ, Jr, Crist CJ, Mann L, Wilson RW. 2002. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 46: 3283-3285.
57. Brown-Elliott BA, et al. 2010. Mycobacterium neoaurum and Mycobacterium bacteremicum sp. nov. as causes of mycobacteremia. J. Clin. Microbiol. 48: 4377-4385.
58. Buchholz UT, McNeill MM, Keyes LE, Good RC. 1998. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin. Infect. Dis. 27: 551-558.
59. Burman WJ, Stone BL, Brown BA, Wallace RJ, Jr, Bottger EC. 1998. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. Diagn. Microbiol. Infect. Dis. 31: 369-371.
60. Burns DN, Rohatgi PK, Rosenthal R, Seiler M, Gordin FM. 1990. Disseminated Mycobacterium fortuitum successfully treated with combination therapy including ciprofloxacin. Am. Rev. Respir. Dis. 142: 468-470.
61. Butler WR, et al. 1999. Mycolic acid pattern standards for HPLC identification of mycobacteria. U.S. Department of Health and Human Services, Washington, DC.
62. Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V. 2006. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin. Infect. Dis. 42: 238-241.
63. Campbell EA, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901-912.
64. Cantón R, del Campo R. 2010. Cystic fibrosis: deciphering the complexity. Eur. Soc. Clin. Microbiol. Infect. Dis. 16: 793-797.
65. Caspers P, et al. 2009. In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs. Antimicrob. Agents Chemother. 53: 3620-3627.
66. Cayrou C, Turenne C, Behr MA, Drancourt M. 2010. Genotyping of Mycobacterium avium complex organisms using multispacer sequence typing. Microbiology 156: 687-694.
67. Chan DCM, Fu H, Forsch RA, Queener SF, Rosowsky A. 2005. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omegacarboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. J. Med. Chem. 48:4420-4431.
68. Chan ED, Kong PM, Fennelly K, Dwyer AP, Iseman MD. 2001. Vertebral osteomyelitis due to infection with nontuberculous Mycobacterium species after blunt trauma to the back: three examples of the principle of locus minoris resistentia. Clin. Infect. Dis. 31:1506-1510.
69. Chandra NS, et al. 2001. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am. J. Ophthalmol. 132: 819-830.
70. Chastellier C, Forquet F, Gordon A, Thilo L. 2009. Mycobacterium requires an all-around closely apposing phagosome membrane to maintain the maturation block and this apposition is re-established when it rescues itself from phagolysosomes. Cell. Microbiol. 11:1190-1207.
71. Chetchotisakd P, et al. 2000. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin. Infect. Dis. 32:29-34.
72. Chio LC, Bolyard LA, Nasr M, Queener SF. 1996. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob. Agents Chemother. 40:727-733.
73. Chocarro A, et al. 1994. Disseminated infection due to Mycobacterium malmoense in a patient infected with human immunodeficiency virus. Clin. Infect. Dis. 19:203-204.
74. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260.
75. Choudhuri BS, Sen S, Chakrabarti P. 1999. Isoniazid accumulation in Mycobacterium smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems. Biochem. Biophys. Res. Commun. 256:682-684.
76. Choueiry MA, Scurto PL, Flynn PM, Rao BN, Hughes WT. 1998. Disseminated infection due to Mycobacterium fortuitum in a patient with desmoid tumor. Clin. Infect. Dis. 26:237-238.
77. Chung MS, Goldstein MH, Driebe WT, Jr, Schwartz BH. 2000. Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. Am. J. Ophthalmol. 129:382-384.
78. Cingolani A, et al. 2000. Disseminated mycobacteriosis caused by drugresistant Mycobacterium triplex in a human immunodeficiency virusinfected patient during highly active antiretroviral therapy. Clin. Infect. Dis. 31:177-179.
79. Cloud JL, et al. 2006. Mycobacterium arupense sp. nov., a novel moderately growing non-chromogenic bacterium isolated from clinical specimens. Int. J. Syst. Evol. Microbiol. 56:1413-1418.
80. Cooksey RC, et al. 2008. Multiphasic approach reveals genetic diversity of environmental and patient isolates of Mycobacterium mucogenicum and Mycobacterium phocaicum associated with an outbreak of bacteremias at a Texas hospital. Appl. Environ. Microbiol. 74:2480-2487.
81. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. 1996. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob. Agents Chemother. 40:1186-1188.
82. Corpe RF. 1981. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev. Infect. Dis. 3:1064-1067.
83. Courvalin P. 2006. Vancomycin resistance in gram-positive cocci. Clin. nfect. Dis. 42(Suppl 1):S25-S34.
84. Cremades R, et al. 2008. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J. Chemother. 20:43-47.
85. Crick DC, Brennan PJ. 2008. Biosynthesis of the arabinogalactanpeptidoglycan complex of Mycobacterium tuberculosis, p 25-40. In Daffé M, Reyrat J-M (ed), The mycobacterial cell envelope. ASM Press, Washington, DC.
86. Cullen AR, Cannon CL, Mark EJ, Colin AA. 2000. Mycobacterium abscessus infection in cystic fibrosis. Am. J. Respir. Crit. Care Med. 161: 641-645.
87. Dabbs ER, Quan S. 2000. Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADPribosylation gene. FEMS Microbiol. Lett. 182:105-109.
88. Dalovisio JR, Pankey GA, Wallace RJ, Jr, Jones DB. 1981. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis. 3:1068-1074.
89. Danelishvilli L, Bermudez LE. 2003. Role of type I cytokines in host defense against Mycobacterium avium infection. Curr. Pharm. Des. 9:61-65.
90. Danilchanka O, Pavlenok M, Niederweis M. 2008. Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob. Agents Chemother. 52:3127-3134.
91. De Rossi, E et al. 1998. Molecular cloning and functional analysis of a novel tetracycline resistance determinant, tet(V), from Mycobacterium smegmatis. Antimicrob. Agents Chemother. 42:1931-1937.
92. Deng L, et al. 1995. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob. Agents Chemother. 39:694-701.
93. Dias MVB, et al. 2007. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. J. Struct. Biol. 159:369-380.
94. Doern GV. 2006. Macrolide and ketolide resistance with Streptococcus pneumoniae. Med. Clin. North Am. 90:1109-1124.
95. Doncker A-V, et al. 2011. Two cases of disseminated Mycobacterium avium infection associated with a new immunodeficiency syndrome related to CXCR4 dysfunctions. Clin. Microbiol. Infect. 17:135-139.
96. Doucet-Populaire F, Capobianco JO, Zakula D, Jarlier V, Goldman RC. 1998. Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother. 41:179-187.
97. Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V. 1995. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J. Antimicrob. Chemother. 36:129-136.
98. Drabick JJ, Duffy PE, Samlaska CP, Scherbenske JM. 1990. Disseminated Mycobacterium chelonae subspecies chelonae infection with cutaneous and osseous manifestations. Arch. Dermatol. 126:1064-1067.
99. Eid AJ, et al. 2007. Prosthetic joint infection due to rapidly growing mycobacteria: report of 8 cases and review of the literature. Clin. Infect. Dis. 45:687-694.
100. Eisenberg E, Barza M. 1994. Azithromycin and clarithromycin. Curr. Clin. Top. Infect. Dis. Chest 14:52-79.
101. El Sahly HM, et al. 2002. Mycobacterium simiae pseudo-outbreak resulting rom a contaminated hospital water supply in Houston, Texas. Clin. Infect. Dis. 35:802-807.
102. Embil J, et al. 1997. Pulmonary illness associated with exposure to Mycobacterium avium complex in hot tub water: hypersensitivity pneumonitis or infection? Chest 111:813-816.
103. Engel HWB, Berwald LG, Havelaar AH. 1980. The occurrence of Mycobacterium kansasii in tap water. Tubercle 61:21-26.
104. Esteban J, et al. 2009. Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria. Int. J. Antimicrob. Agents 34:454-456.
105. Fanti, F et al. 2004. Mycobacterium parmense sp. nov. Int. J. Syst. Evol. Microbiol. 54:1123-1127.
106. Fattorini L, et al. 1992. Resistance to beta-lactams in Mycobacterium fortuitum. Antimicrob. Agents Chemother. 36:1068-1072.
107. Fattorini L, et al. 1991. Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics. Antimicrob. Agents Chemother. 35:1760-1764.
108. Fauroux B, et al. 1997. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr. Infect. Dis. J. 16:354-358.
109. Fernández-Roblas R, et al. 2008. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob. Agents Chemother. 52:4184-4186.
110. Finken M, Kirschner P, Meier A, Wrede A, Bottger EC. 1993. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol. Microbiol. 9:1239-1246.
111. Flensburg J, Skold O. 1987. Massive overproduction of dihydrofolate reductase in bacteria as a response to the use of trimethoprim. Eur. J. Biochem. 162:473-476.
112. Flor A, Capdevila JA, Martin N, Gavaldà J, Pahissa A. 1996. Nontuberculous mycobacterial meningitis: report of two cases and review. Clin. Infect. Dis. 23:1266-1273.
113. Flores AR, Parsons LM, Pavelka MS, Jr. 2005. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology 151: 521-532.
114. Forbes BA, et al. 2008. Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A. Clinical and Laboratory Standards Institute, Wayne, PA.
115. Ford JG, et al. 1998. Nontuberculous mycobacterial keratitis in south Florida. Ophthalmology 5:1652-1658.
116. Forsch RA, Queener SF, Rosowsky A. 2004. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium. Bioorg. Med. Chem. Lett. 14:1811-1815. (Erratum, 14:2693.)
117. Franklin DJ, Starke JR, Brady MT, Brown BA, Wallace RJ, Jr. 1994. Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Am. J. Otol. 15:313-320.
118. Freitas, D et al. 2003. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology 110: 276-285.
119. Friedman ND, Sexton DJ. 2001. Bursitis due to Mycobacterium goodii, a recently described, rapidly growing mycobacterium. J. Clin. Microbiol. 39:404-405.
120. Frothingham R, Wilson KH. 1993. Sequence-based differentiation of strains in the Mycobacterium avium complex. J. Bacteriol. 175:2818-2825.
121. Frothingham R, Wilson KH. 1994. Molecular phylogeny of the Mycobacterium avium complex demonstrates clinically meaningful divisions. J. Infect. Dis. 169:305-312.
122. Fuji K, Saito H, Tomioka H, Mae T, Hosoe K. 1995. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob. Agents Chemother. 39:1489-1492.
123. Fujita J, et al. 2003. Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex. Respir. Med. 97:933-938.
124. Gannon M, Otridge B, Hone R, Dervan P, O'Loughlin S. 1990. Cutaneous Mycobacterium malmoense infection in an immunocompromised patient. Int. J. Dermatol. 29:149-150.
125. Garza-Ramos G, Xiong L, Zhong P, Mankin A. 2001. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J. Bacteriol. 183:6898-6907.
126. Gaynor CD, et al. 1994. Disseminated Mycobacterium genavense infection in two patients with AIDS. Clin. Infect. Dis. 18:455-457.
127. Gibson RL, et al. 2003. Significant microbiological effect of inhaled obramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 167:841-849.
128. Gillis TP, Williams DL. 2000. Dapsone resistance in Mycobacterium leprae. Lepr. Rev. 71(Suppl):S91-S95.
129. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. 1999.Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur. Respir. J. 14:347-351.
130. Gordin FM, et al. 1999. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28:1080-1085.
131. Griffith DE. 2010. Nontuberculous mycobacterial lung disease. Curr. Opin. Infect. Dis. 23:185-190.
132. Griffith DE, et al. 2007. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. American Thoracic Society Statement. Am. J. Respir. Crit. Care Med. 175:367-416.
133. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ. 2000. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin.Infect. Dis. 30:288-292.
134. Griffith DE, et al. 2001. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 32:1547-1553.
135. Griffith DE, Brown BA, Girard WM, Wallace RJ, Jr. 1995. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 21:594-598.
136. Griffith DE, et al. 1998. Initial (6 month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J. Infect. Dis. 178:121-126.
137. Griffith DE, Brown BA, Wallace RJ, Jr. 1996. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin. Infect. Dis. 23:1321-1322.
138. Griffith DE, Jr, et al. 2006. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 174:928-934.
139. Griffith DE, Jr, et al. 2005. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 172:250-253.
140. Griffith DE, Brown-Elliott BA, Wallace RJ, Jr. 2003. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin. Infect. Dis. 37:1178-1182.
141. Griffith DE, Girard WM, Wallace RJ, Jr. 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: analysis of 154 patients. Am. Rev. Respir. Dis. 147:1271-1278.
142. Gruenberg DA, et al. 2010. Atypical presentation of IL-12 receptor beta1 deficiency with pneumococcal sepsis and disseminated nontuberculous mycobacterial infection in a 19-month-old girl born to nonconsanguineous US residents. J. Allergy Clin. Immunol. 125:264-265.
143. Guillemin I, et al. 1999. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. Microbiology 145:2527-2532.
144. Haerynck F, et al. 2008. Disseminated Mycobacterium avium infection in a patient with a novel mutation in the interleukin-12 receptor-beta1 chain. J. Pediatr. 153:721-722.
145. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. 2005. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J. Clin. Microbiol. 43:4407-4412.
146. Han JI, Rosenzweig SD, Church JA, Holland SM, Ross LA. 2004. Variable presentation of disseminated nontuberculous mycobacterial infections in a family with an interferon-gamma receptor mutation. Clin. Infect. Dis. 39:868-870.
147. Hansen JL, et al. 2002. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell 10:117-128.
148. Hasegawa N, et al. 2009. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 136:1569-1575.
149. Heginbothom ML, Lindholm-Levy PJ, Heifets LB. 1998. Susceptibilities of Mycobacterium malmoense determined at the growth optimumpH (pH 6.0). Int. J. Tuberc. Lung Dis. 2:430-434.
150. Helm CJ, Holland GN, Lin R, Berlin OGW, Bruckner DA. 1993. Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model. Am. J. Ophthalmol. 116:700-707.
151. Henriques B, et al. 1994. Infection with Mycobacterium malmoense in Sweden: report of 221 cases. Clin. Infect. Dis. 18:596-600.
152. Hernández-Garduño E, Elwood RK. 2010. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg. Infect. Dis. 16: 1047.
153. Herold RC, Lotke PA, MacGregor RR. 1987. Prosthetic joint infections secondary to rapidly growing Mycobacterium fortuitum. Clin. Orthop. Relat. Res. 216:183-186.
154. Hillemann D, Rusch-Gerdes S, Richter E. 2008. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother. 52:800-801.
155. Ho II, Chan CY, Cheng AF. 2000. Aminoglycoside resistance in Mycobacterium kansasii, Mycobacterium avium-M. intracellulare, and Mycobacterium fortuitum: are aminoglycoside-modifying enzymes responsible? Antimicrob. Agents Chemother. 44:39-42.
156. Hobbie SN, et al. 2006. Binding of neomycin-class aminoglycoside antibiotics to mutant ribosomes with alterations in the A site of 16S rRNA. Antimicrob. Agents Chemother. 50:1489-1496.
157. Hoefsloot W, et al. 2009. Clinical relevance of Mycobacterium malmoense isolation in the Netherlands. Eur. Respir. J. 34:926-931.
158. Hoff E, et al. 2001. Mycobacterium triplex infection in a liver transplant patient. J. Clin. Microbiol. 39:2033-2034.
159. Hoffner SE, Klintz L, Olsson-Lijequist B, Bolmström A. 1994. Evaluation of Etest for rapidly growing susceptibility testing of Mycobacterium chelonae and M. fortuitum. J. Clin. Microbiol. 32:1846-1849.
160. Holmes GP, Bond GB, Fader RC, Fulcher SF. 2002. A cluster of cases of Mycobacterium szulgai keratitis that occurred after laser-assisted in situ keratomileusis. Clin. Infect. Dis. 34:1039-1046.
161. Holzel CS, Harms KS, Schwaiger K, Bauer J. 2010. Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4. Antimicrob. Agents Chemother. 54:1351-1353.
162. Honore N, Cole ST. 1994. Streptomycin resistance in mycobacteria. Antimicrob. Agents Chemother. 38:238-242.
163. Horsburgh CR, Jr, Mason UG, Farhi DC, Iseman MD. 1985. Disseminated infection with Mycobacterium avium-intracellulare. Medicine 64: 36-48.
164. Horsburgh CR, Selik RM. 1989. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am. Rev. Respir. Dis. 139:4-7.
165. Hugonnet J-E, Blanchard JS. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46: 1998-2004.
166. Hugonnet J-E, Tremblay LW, Boshoff HI, Barry CE III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218.
167. Hui J, Gordon N, Kajioka R. 1977. Permeability barrier to rifampin in mycobacteria. Antimicrob. Agents Chemother. 11:773-779.
168. Hull SI, et al. 1984. Presence of aminoglycoside acetyltransferase and plasmids in Mycobacterium fortuitum. Lack of correlation with intrinsic aminoglycoside resistance. Am. Rev. Respir. Dis. 129:614-618.
169. Huovinen P, Sundstrom L, Swedberg G, Skold O. 1995. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
170. Huth RG, Brown-Elliott BA, Wallace RJ, Jr. 2011. Mycobacterium mageritense pulmonary disease in patient with compromised immune system. Emerg. Infect. Dis. 17:556-558.
171. Hyon J-Y, et al. 2004. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Arch. Ophthalmol. 122:1166-1169.
172. Inderlied CB, Young LS, Yamada JK. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob. Agents Chemother. 31: 1697-1702.
173. Ingram CW, Tanner DC, Durack DT, Kernodle GW, Jr, Corey GR. 1993. Disseminated infection with rapidly growing mycobacteria. Clin. Infect. Dis. 16:463-471.
174. Ippolito JA, et al. 2008. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51:3353-3356.
175. Iseman MD, Corpe RF, O'Brien RJ, Rosenzwieg DY, Wolinsky E. 1985. Disease due to Mycobacterium avium-intracellulare. Chest 87(2 Suppl):139S-149S.
176. Jadeja L, Bolivar R, Wallace RJ, Jr, Silcox VA, Bodey GP. 1983. Bacteremia caused by a previously unidentified species of rapidly growing Mycobacterium successfully treated with vancomycin. Ann. Intern. Med. 99:475-477.
177. Jarlier V, Gutmann L, Nikaido H. 1991. Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae. Antimicrob. Agents Chemother. 35:
178. Jeon K, et al. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease. Am. J. Respir. Crit. Care Med. 180:896-902.
179. Jernigan JA, Farr BM. 2000. Incubation period and sources for cutaneous Mycobacterium marinum infection: case report and review of the literature. Clin. Infect. Dis. 31:439-443.
180. Jönsson BE, et al. 2007. Molecular epidemiology of Mycobacterium abscessus with focus on cystic fibrosis. J. Clin. Microbiol. 45:1497-1504.
181. Kanatani MS, Guglietmo BJ. 1994. The new macrolides: azithromycin and clarithromycin. West. J. Med. 160:31-37.
182. Kasik JE. 1965. The nature of mycobacterial penicillinase. Am. Rev. Respir. Dis. 91:117-119.
183. Kasik JE, Monick M, Schwarz B. 1980. Beta-lactamase activity in slowgrowing nonpigmented mycobacteria and their sensitivity to certain beta-lactam antibiotics. Tubercle 61:213-219.
184. Kasik JE, Severson CD, Stearns NA, Thompson JS. 1971. Immunologic distinction of mycobacterial beta-lactamase. J. Lab. Clin. Med. 78:982.
185. Kasik JE, Weber M, Freehill PJ. 1967. The effect of the penicillinaseresistant penicillins and other chemotherapeutic substances on the penicillinase of the R1Rv strain of Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 95:12-19.
186. Kenney TJ, Churchward G. 1994. Cloning and sequence analysis of the rpsL and rpsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin. J. Bacteriol. 176:6153-6156.
187. Kilby JM, et al. 1992. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 102:70-75.
188. Kim RD, et al. 2008. Pulmonary nontuberculous mycobacterial disease. Prospective study of a distinct preexisting syndrome. Am. J. Respir. Crit. Care Med. 178:1066-1074.
189. Kim HY, et al. 2010. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol. Immunol. 54:347-353.
190. Klein JL, Brown TJ, French GL. 2001. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob. Agents Chemother. 45:3056-3058.
191. Kobashi Y, Matsushima T, Oka M. 2007. A double-blind randomized study of aminoglycosides infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 101:130-138.
192. Kobashi Y, Yoshida K, Miyashita N, Oka M. 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12:195-202.
193. Koh W-J, et al. 2011. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am. J. Respir. Crit. Care Med. 183:405-410.
194. Kompis IM, Islam K, Then RL. 2005. DNA and RNA synthesis: antifolates. Chem. Rev. 105:593-620.
195. Kongpetchsatit O, et al. 2006. Mutation in the rpoB gene of the rifampicin resistant M. avium complex strains from Thailand. Southeast Asian J. Trop. Med. Public Health 37(Suppl 3):165-173.
196. Korzheva N, et al. 2000. A structural model of transcription elongation. Science 289:619-625.
197. Kremer L, et al. 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278:20547-20554.
198. Kulkarni VM, Seydel JK. 1983. Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from Mycobacterium lufu and Mycobacterium leprae. A comparison. Chemotherapy 29:58-67.
199. Lai C-C, et al. 2010. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg. Infect. Dis. 16:294-296.
200. Lam PK, et al. 2006. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 173:1283-1289.
201. Lamy B, Marchandin H, Hamitouche K, Laurent F. 2008. Mycobacterium setense sp. nov., a Mycobacterium fortuitum group organism isolated from a patient with soft tissue infection and osteitis. Int. J. Syst. Evol. Microbiol. 58:486-490.
202. Lang-Lazdunski L, et al. 2001. Pulmonary resection for Mycobacterium xenopi pulmonary infection. Ann. Thorac. Surg. 72:1877-1882.
203. Larsen MH, et al. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
204. Lavollay M, et al. 2008. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190:4360-4366.
205. Lavollay M, et al. 2011. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases. J. Bacteriol. 193: 778-782.
206. Ledala N, Wilkinson BJ, Jayaswal RK. 2006. Effects of oxacillin and tetracycline on autolysis, autolysin processing and atl transcription in Staphylococcus aureus. Int. J. Antimicrob. Agents 27:518-524.
207. Lee RE, Mikusova K, Brennan PJ, Besra GS. 1995. Synthesis of the mycobacterial arabinose donor_ -D-arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic arabinosyltransferase assay, and identification of ethambutol as an arabinosyl transferase inhibitor. J. Am. Chem. Soc. 117:11829-11832.
208. Lee SA, Raad II, Adachi JA, Han XY. 2004. Catheter-related bloodstream infection caused by Mycobacterium brumae. J. Clin. Microbiol. 42:5429-5431.
209. Lee SB, et al. 2001. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Ann. Trop. Med. Parasitol. 95:429-432.
210. Lety MA, Nair S, Berche P, Escuyer V. 1997. A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 41:2629-2633.
211. Levendoglu-Tugal O, et al. 1998. Infections due to nontuberculous mycobacteria in children with leukemia. Clin. Infect. Dis. 27:1227-1230.
212. Levin ME, Hatfull GF. 1993. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol. Microbiol. 8:277-285.
213. Levy I, et al. 2008. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg. Infect. Dis. 14:378-384.
214. Lewis FM, Marsh BJ, von Reyn CF. 2003. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin. Infect. Dis. 37:390-397.
215. Li XZ, Zhang L, Nikaido H. 2004. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415-2423.
216. Lillo M, Orengo S, Cernoch P, Harris RL. 1990. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev. Infect. Dis. 2:760-767.
217. Lincoln EM, Gilbert LA. 1972. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 105:683-714.
218. LiPuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323.
219. Liu J, Takiff HE, Nikaido H. 1996. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J. Bacteriol. 178:3791-3795.
220. Liu M, Douthwaite S. 2002. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob. Agents Chemother. 46:1629-1633.
221. Locke JB, et al. 2010. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 54:5337-5343.
222. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
223. Locke JB, et al. 2010. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob. Agents Chemother. 54:5352-5355.
224. Long KS, et al. 2010. Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance. Antimicrob. Agents Chemother. 54:4705-4713.
225. MacSwiggan DA, Collins CH. 1974. The isolation of M. kansasii and M. xenopi from water systems. Tubercle 55:291-297.
226. Madsen CT, et al. 2005. Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis. J. Biol. Chem. 280:38942-38947.
227. Madsen CT, Jakobsen L, Douthwaite S. 2005. Mycobacterium smegmatis Erm(38) is a reluctant dimethyltransferase. Antimicrob. Agents Chemother. 49:3803-3809.
228. Mahapatra S, Scherman H, Brennan PJ, Crick DC. 2005. N glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment. J. Bacteriol. 187:2341-2347.
229. Mainardi JL, et al. 2000. Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J. Biol. Chem. 275:16490-16496.
230. Maniu CV, Hellinger WC, Chu S-Y, Palmer R, Alvarez-Elcoro S. 2001. Failure treatment of chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid. Clin. Infect. Dis. 33:745-748.
231. Marras TK, Wallace R, Jr, Koth LL, Stulbarg MS. 2005. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 127:664-671.
232. Martin R, Mogg AE, Heywood LA, Nitschke L, Burke JF. 1989. Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells. Mol. Gen. Genet. 217:411-418.
233. Matsuoka M, et al. 2008. A novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries. J. Med. Microbiol. 57:1213-1219.
234. Maxson S, Schutze GE, Jacobs RF. 1994. Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infect. Dis. Clin. Pract. 3:203-204.
235. McGarvey J, Bermudez L. 2002. Pathogenesis of nontuberculous mycobacteria infections. Clin. Chest Med. 23:1-15.
236. Mdluli K, et al. 1998. Inhibition of a Mycobacterium tuberculosis betaketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
237. Meier A, et al. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174:354-360.
238. Meier A, Kirschner P, Bange FC, Vogel U, Bottger EC. 1994. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob. Agents Chemother. 38:228-233.
239. Meier A, et al. 1994. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob. Agents Chemother. 38:381-384.
240. Meier A, Sander P, Schaper KJ, Scholz M, Bottger EC. 1996. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2452-2454.
241. Meka VG, et al. 2004. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J. Antimicrob. Chemother. 54: 818-820.
242. Meka VG, et al. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
243. Mendes RE, et al. 2010. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J. Clin. Microbiol. 48:3041-3043.
244. Metcalf JF, John JF, Jr, Wilson GB, Fudenberg HH, Harley RA. 1981. Mycobacterium fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am. J. Med. 71:485-492.
245. Miesel L, Rozwarski DA, Sacchettini JC, Jacobs WR, Jr. 1998. Mechanisms for isoniazid action and resistance. Novartis Found. Symp. 217: 209-220.
246. Mikusova K, Slayden RA, Besra GS, Brennan PJ. 1995. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother. 39:2484-2489.
247. Moerman M, Dierick J, Mestdagh J, Boedts D, Van Cauwenberge P. 1993. Mastoiditis caused by atypical mycobacteria. Int. J. Pediatr. Otorhinolaryngol. 28:69-76.
248. Moghazeh SL, et al. 1996. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampinresistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40:2655-2657.
249. Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. 2002. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing. J. Clin. Microbiol. 40:3810-3813.
250. Moore IF, Hughes DW, Wright GD. 2005. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 44:11829-11835.
251. Moran JF, Alexander LG, Staub EW, Young WG, Sealy WC. 1983. Long-term results of pulmonary resection for atypical mycobacterial disease. Ann. Thorac. Surg. 35:597-604.
252. Mukhopadhyay S, Chakrabarti P. 1997. Altered permeability and betalactam resistance in a mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 41:1721-1724.
253. Murcia MI, Tortoli E, Menendez MC, Palenque E, Garcia MJ. 2006. Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant. Int. J. Syst. Evol. Microbiol. 56:2049-2054.
254. Murray MP, Laurenson IF, Hill AT. 2008. Outcome of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin. Infect. Dis. 47:222-224.
255. Murray R, Mallal S, Heath C, French M. 2001. Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation therapy for disseminated Mycobacterium avium complex infection. Eur. J. Clin. Microbiol. Infect. Dis. 20:199-201.
256. Musser JM, et al. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173: 196-202.
257. Nachamkin I, Kang C, Weinstein MP. 1997. Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin. Infect. Dis. 24:894-900.
258. Nair J, Rouse DA, Bai GH, Morris SL. 1993. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol. Microbiol. 10:521-527.
259. Narang R, et al. 2010. Disseminated disease caused by Mycobacterium simiae in AIDS patients: a report of three cases. Clin. Microbiol. Infect. 15:912-914.
260. Nash DR, et al. 1986. Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility. Am. Rev. Respir. Dis. 134:1276-1282.
261. Nash KA. 2003. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Antimicrob. Agents Chemother. 47:3053-3060.
262. Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ, Jr. 2006. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob. Agents Chemother. 50:3476-3478.
263. Nash KA, Brown-Elliott BA, Wallace RJ, Jr. 2009. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 53:1367-1376.
264. Nash KA, Inderlied CB. 1995. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 39:2625-2630.
265. Nash KA, Inderlied CB. 1996. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Antimicrob. Agents Chemother. 40:1748-1750.
266. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ, Jr. 2005. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J. Antimicrob. Chemother. 55:170-177.
267. Neitch SM, Sydnor JB, Schleupner CJ. 1982. Mycobacterium fortuitum as a cause of mastoiditis and wound infection. Arch. Otolaryngol. Head Neck Surg. 108:11-14.
268. Nelson KG, Griffith DE, Brown BA, Wallace RJ, Jr. 1998. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg. 66:325-330.
269. Nelson KG, Griffith DE, Wallace RJ, Jr. 2004. Pulmonary mycobacterial disease. The role of surgical resection. Clin. Pulm. Med. 11:355-362.
270. Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B. 2002. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2137-2144.
271. Niobe SN, et al. 2001. Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J. Clin. Microbiol. 39:2030-2032.
272. Nopponpunth V, Sirawaraporn W, Greene PJ, Santi DV. 1999. Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J. Bacteriol. 181: 6814-6821.
273. Novak P, Tatic I, Tepes P, Kostrun S, Barber J. 2006. Systematic approach to understanding macrolide-ribosome interactions: NMR and modeling studies of oleandomycin and its derivatives. J. Phys. Chem. A 110:572-579.
274. Novi C, Rindi L, Lari N, Garzelli C. 2000. Molecular typing of Mycobacterium avium isolates by sequencing of the 16S-23S rDNA internal transcribed spacer and comparison with IS1245-based fingerprinting. J. Med. Microbiol. 49:1091-1095.
275. Obata S, et al. 2006. Association of rpoB mutations with rifampicin resistance in Mycobacterium avium. Int. J. Antimicrob. Agents 27:32-39.
276. Olivier KN, et al. 2003. Nontuberculous mycobacteria. II. Nestedcohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167:835-840.
277. Olivier KN, et al. 2003. Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167: 828-834.
278. Olson MW, et al. 2006. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50: 2156-2166.
279. Pang Y, Brown BA, Steingrube VA, Wallace RJ, Jr, Roberts MC. 1994. Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob. Agents Chemother. 38:1408-1412.
280. Paone RF, Mercer LC, Glass BA. 1991. Pneumonectomy secondary to Mycobacterium fortuitum in infancy. Ann. Thorac. Surg. 51:1010-1011.
281. Park YK, et al. 2002. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6:166-170.
282. Patel SY, Doffinger R, Barcenas-Morales G, Kumararatne DS. 2008. Genetically determined susceptibility to mycobacterial infection. J. Clin. Pathol. 61:1006-1012.
283. Paulin LG, Brander EE, Poso HJ. 1985. Specific inhibition of spermidine synthesis in Mycobacteria spp. by the dextro isomer of ethambutol. Antimicrob. Agents Chemother. 28:157-159.
284. Pennekamp A, Pfyffer GE, Wüest J, George CA, Ruef C. 1997. Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Ann. Plast. Surg. 39:80-83.
285. Pfister P, et al. 2005. Mutagenesis of 16S rRNA C1409-G1491 base-pair differentiates between 6=OHand 6=NH3_aminoglycosides. J. Mol. Biol. 346:467-475.
286. Pfister P, et al. 2004. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J. Mol. Biol. 342:1569-1581.
287. Piddock LJ, Williams KJ, Ricci V. 2000. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45:159-165.
288. Pierre-Audigier C, et al. 2005. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J. Clin. Microbiol. 43:3467-3470.
289. Piersimoni C, et al. 2004. Mycobacterium lentiflavum as an emerging causative agent of cervical lymphadenitis. J. Clin. Microbiol. 42:3894-3897.
290. Piersimoni C, et al. 1997. Isolation of Mycobacterium celatum from patients infected with human immunodeficiency virus. Clin. Infect. Dis. 24:144-147.
291. Piersimoni C, Zitti PG, Nista D, Bornigia S. 2003. Mycobacterium celatum pulmonary infection in the immunocompetent: case report and review. Emerg. Infect. Dis. 9:399-402.
292. Pioletti M, et al. 2001. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20:1829-1839.
293. Piton J, et al. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245. doi:10.1371/journal.pone.0012245.
294. Plaus WJ, Hermann G. 1991. The surgical management of superficial infections caused by atypical mycobacteria. Surgery 110:99-103.
295. Plemmons RM, McAllister CK, Garces MC, Ward RL. 1997. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin. Infect. Dis. 24:995-997.
296. Pomerantz M, et al. 1996. Resection of the right middle lobe and lingual for mycobacterial infection. Ann. Thorac. Surg. 62:990-993.
297. Poole K. 2001. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 3:255-264.
298. Poso H, Paulin L, Brander E. 1983. Specific inhibition of spermidine synthase from mycobacteria by ethambutol. Lancet 2:1418.
299. Prammananan T, Phunpruch S, Tingtoy N, Srimuang S, Chaiprasert A. 2006. Distribution of hsp65 PCR-restriction enzyme analysis patterns among Mycobacterium avium complex isolates in Thailand. J. Clin. Microbiol. 44:3819-3821.
300. Prammananan T, et al. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581.
301. Projan SJ. 2000. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20:219S-223S.
302. Quan S, Venter H, Dabbs ER. 1997. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob. Agents Chemother. 41: 2456-2460.
303. Quinting B, et al. 1997. Contribution of beta-lactamase production to the resistance of mycobacteria to beta-lactam antibiotics. FEBS Lett. 406: 275-278.
304. Raad II, Vartivarian S, Khan A, Bodey GP. 1991. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev. Infect. Dis. 13:1120-1125.
305. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29.
306. Ramaswamy SV, et al. 2000. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:326-336.
307. Ramon-Garcia S, Martin C, Ainsa JA, De Rossi E. 2006. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 57:252-259.
308. Ramon-Garcia S, Oral I, Martin C, Gomez-Lus R, Ainsa JA. 2006. Novel streptomycin resistance gene from Mycobacterium fortuitum. Antimicrob. Agents Chemother. 50:3920-3922.
309. Rapkiewicz AV, Patel SY, Holland SM, Kleiner DE. 2007. Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-gamma receptor 2 deficiency. Virchows Arch. 451: 95-100.
310. Rappaport W, et al. 1990. The surgical management of atypical mycobacterial soft-tissue infections. Surgery 108:36-39.
311. Rastogi N, Labrousse V. 1991. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob. Agents Chemother. 35:462-470.
312. Redelman-Sidi G, Sepkowitz KA. 2010. Rapidly growing mycobacteria infection in patients with cancer. Clin. Infect. Dis. 51:422-434.
313. Research Committee of the British Thoracic Society. 2001. First randomized trial treatments for pulmonary disease caused by M. aviumintracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167-172.
314. Research Committee of the British Thoracic Society. 2002. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int. J. Tuberc. Lung Dis. 67:628-634.
315. Research Committee of the British Thoracic Society. 2003. Pulmonary disease caused by M. malmoense in HIV negative patients: 5 year follow-up of patients receiving standardized treatment. Eur. Respir. J. 21: 478-482.
316. Riccardi G, Pasca MR, Buroni S. 2009. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol. 4:597-614.
317. Richter E, Rüsch-Gerdes S, Hillemann D. 2007. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1534-1536.
318. Ridderhof JC, et al. 1991. Chronic tenosynovitis of the hand due to Mycobacterium nonchromogenicum: use of high-performance liquid chromatography for identification of isolates. Rev. Infect. Dis. 13:857-864.
319. Roberts MC. 2011. Nomenclature Center for MLS Genes. University of Washington, Seattle, WA. http://faculty.washington.edu/marilynr/.320.
320. Roberts MC. 2005. Update on acquired tetracycline resistance genes. FEMS Microbiol. Lett. 245:195-203.
321. Roberts MC, et al. 1999. Nomenclature for macrolide and macrolidelincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.
322. Rocco JM, Irani VR. 2011. Mycobacterium avium and modulation of the host macrophage immune mechanisms. Int. J. Tuberc. Lung Dis. 15:447-452.
323. Rodrigues L, Ramos J, Couto I, Amaral L, Viveiros M. 2011. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol. 11:35. doi:10.1186/1471-2180-11-35.
324. Rodrigues L, et al. 2009. The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int. J. Antimicrob. Agents 34: 529-533.
325. Rosenzweig SD, Holland SM. 2005. Defects in the interferon-gamma and interleukin-12 pathways. Immunol. Rev. 203:38-47.
326. Rosowsky A, Forsch RA, Sibley CH, Inderlied CB, Queener SF. 2004. New 2,4-diamino-5-(2=,5=-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. J. Med. Chem. 47:1475-1486. (Erratum, 47:3705.)
327. Ross JI, Eady EA, Cove JH, Cunliffe WJ. 1998. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob. Agents Chemother. 42:1702-1705.
328. Rossi-Fedele G, Scott W, Spratt D, Gulabivala K, Roberts AP. 2006. Incidence and behaviour of Tn916-like elements within tetracyclineresistant bacteria isolated from root canals. Oral Microbiol. Immunol. 21:218-222.
329. Roux A-L, et al. 2009. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J. Clin. Microbiol. 47:4124-4128.
330. Safdar A, Han XY. 2005. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species: clinical significance in immunosuppressed cancer patients and summary of reported cases of infection. Eur. J. Clin. Microbiol. Infect. Dis. 24:554-558.
331. Saiman L, et al. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. J. Am. Med. Assoc. 290:1749-1756.
332. Saiman L, Siegel J. 2004. Infection control in cystic fibrosis. Clin. Microbiol. Rev. 17:57-71.
333. Salah IB, Cayrou C, Raoult D, Drancourt M. 2009. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., members of the Mycobacterium avium complex. Int. J. Syst. Evol. Microbiol. 59:2803-2808.
334. Sampaio JLM, et al. 2006. An outbreak of keratitis caused by Mycobacterium immunogenum. J. Clin. Microbiol. 44:3201-3207.
335. Sander P, et al. 2002. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol. Microbiol. 46:1295-1304.
336. Sander P, et al. 2000. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol. Lett. 193:19-23.
337. Sanguinetti M, et al. 2001. Fatal pulmonary infection due to multidrugresistant Mycobacterium abscessus in a patient with cystic fibrosis. J. Clin. Microbiol. 39:816-819.
338. Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. 1996. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin. Microbiol. Rev. 9:435-447.
339. Schinsky MF, et al. 2000. Mycobacterium septicum sp. nov., a new rapidly growing species associated with catheter-related bacteraemia. Int. J. Syst. Evol. Microbiol. 50:575-581.
340. Schinsky MF, et al. 2004. Taxonomic variation in the Mycobacterium fortuitum third-biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov., Mycobacterium brisbanense sp. nov., and recognition of Mycobacterium porcinum from human clinical isolates. Int. J. Syst. Evol. Microbiol. 54:1653-1667.
341. Schlunzen F, et al. 2003. Structural basis for the antibiotic activity of ketolides and azalides. Structure (Camb.) 11:329-338.
342. Schröder KH, Juhlin I. 1977. Mycobacterium malmoense sp. nov. Int. J. Syst. Bacteriol. 27:241-246.
343. Schroeder R, Waldsich C, Wank H. 2000. Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 19:1-9.
344. Sermet-Gaudelus I, et al. 2003. Mycobacterium abscessus and children with cystic fibrosis. Emerg. Infect. Dis. 9:1587-1591.
345. Shafran SD, et al. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N. Engl. J. Med. 335:377-383.
346. Shah IM, Dworkin J. 2010. Induction and regulation of a secreted peptidoglycan hydrolase by a membrane Ser/Thr kinase that detects muropeptides. Mol. Microbiol. 75:1232-1243.
347. Shah MK, Sebti A, Kiehn TE, Massarella SA, Sepkowitz KA. 2001. Mycobacterium haemophilum in immunocompromised patients. Clin. Infect. Dis. 33:330-337.
348. Shaw KJ, Rather PN, Hare RS, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57:138-163.
349. Shiraishi Y, Fukushima K, Komatsu H, Kurashima A. 1998. Early pulmonary resection for localized Mycobacterium avium complex disease. Ann. Thorac. Surg. 66:183-186.
350. Shiraishi Y, et al. 2002. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur. J. Cardiothorac. Surg. 21:314-318.
351. Simor AE, Salit IE, Vellend H. 1984. The role of Mycobacterium xenopi in human disease. Am. Rev. Respir. Dis. 129:435-438.
352. Sirawaraporn W, Sirawaraporn R, Chanpongsri A, Jacobs WR, Jr, Santi DV. 1991. Purification and characterization of dihydrofolate reductase from wild-type and trimethoprim-resistant Mycobacterium smegmatis. Exp. Parasitol. 72:184-190.
353. Skold O. 2001. Resistance to trimethoprim and sulfonamides. Vet. Res. 32:261-273.
354. Skold O. 2010. Sulfonamides and trimethoprim. Expert Rev. Anti Infect. Ther. 8:1-6.
355. Slayden RA, Barry CE III. 2002. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis 82:149-160.
356. Slayden RA, Lee RE, Barry CE III. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525.
357. Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL. 2000. Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing. Clin. Infect. Dis. 30:444-453.
358. Springer B, et al. 2001. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob. Agents Chemother. 45:2877-2884.
359. Springer B, et al. 1995. Mycobacterium conspicuum sp. nov., a new species isolated from patients with disseminated infections. J. Clin. Microbiol. 33:2805-2811.
360. Sreevatsan S, et al. 1996. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob. Agents Chemother. 40:1024-1026.
361. Steadham JE, Stall SK, Simmank JL. 1985. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex. Diagn. Microbiol. Infect. Dis. 3:33-40.
362. Stephan J, et al. 2005. The growth rate of Mycobacterium smegmatis epends on sufficient porin-mediated influx of nutrients. Mol. Microbiol. 58:714-730.
363. Stephan J, et al. 2004. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:4163-4170.
364. Stone MS, Wallace RJ, Jr, Swenson JM, Thornsberry C, Christensen LA. 1983. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob. Agents Chemother. 24:486-493.
365. Stout JE, et al. 2008. Association between 16S-23S internal transcribed spacer sequence groups of Mycobacterium avium complex and pulmonary disease. J. Clin. Microbiol. 46:2790-2793.
366. Suling WJ, et al. 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 42: 811-815.
367. Suomalainen S, et al. 2001. Pulmonary infection caused by an unusual, slowly growing nontuberculous Mycobacterium. J. Clin. Microbiol. 39: 2668-2671.
368. Swanson DS, et al. 1997. Subspecific differentiation of Mycobacterium avium complex strains by automated sequencing of a region of the gene (hsp65) encoding a 65-kilodalton heat shock protein. Int. J. Syst. Bacteriol. 47:414-419.
369. Swenson JM, Wallace RJ, Jr, Silcox VA, Thornsberry C. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28:807-811.
370. Takayama K, Davidson LA. 1979. Isonicotinic acid hydrazide, p 98-119. In Hahn FE (ed), Mechanism of action of antibacterial agents, vol 5. Springer-Verlag, Berlin, Germany.
371. Takayama K, Kilburn JO. 1989. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33:1493-1499.
372. Takayama K, Schnoes HK, Armstrong EL, Boyle RW. 1975. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res. 16:308-317.
373. Takiff HE, et al. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. U. S. A. 93:362-366.
374. Tan KH-V, Mulheran M, Knox AJ, Smyth AR. 2003. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167:819-823.
375. Tanaka E, et al. 1997. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med. 155:2041-2046.
376. Taylor JL, Palmer SM. 2006. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J. Heart Lung Transplant. 25:985-988.
377. Tebas P, Sultan F, Wallace RJ, Jr, Fraser V. 1995. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin. Infect. Dis. 20:443-444.
378. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
379. Telenti A, et al. 1997. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3:567-570.
380. Thomsen VØ, Dragsted UB, Bauer J, Fuursted K, Lundgren J. 1999. Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J. Clin. Microbiol. 37:3901-3905.
381. Thomson RM. 2010. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg. Infect. Dis. 16:1576-1583.
382. Toh S-M, et al. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
383. Tompkins JC, Harrison MS, Witzig RS. 2008. Mycobacterium goodie infection of a total knee prosthesis. Infect. Med. 25:522-525.
384. Torkko P, et al. 2002. Mycobacterium palustre sp. nov., a potentially pathogenic, slowly growing mycobacterium isolated form clinical and veterinary specimens and from Finnish stream waters. Int. J. Syst. Evol. Microbiol. 52:1519-1525.
385. Tortoli E. 2003. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin. Microbiol. Rev. 16:319-354.
386. Tortoli E. 2004. Clinical features of infections caused by new nontuberculous mycobacteria, part 1. Clin. Microbiol. Newsl. 26:89-96.
387. Tortoli E. 2006. The new mycobacteria: an update. FEMS Immunol. Med. Microbiol. 48: 159-178.
388. Tortoli E, et al. 2009. Pulmonary disease due to Mycobacterium arosiense, an easily misidentified pathogenic novel mycobacterium. J. Clin. Microbiol. 47:1947-1949.
389. Tortoli E, et al. 1998. Pulmonary infection due to Mycobacterium szulgai, case report and review of the literature. Eur. Respir. J. 11:975-977.
390. Tortoli E, et al. 1999. Mycobacterium tusciae sp. nov. Int. J. Syst. Bacteriol. 49:1839-1844.
391. Tortoli E, et al. 1997. Characterization of mycobacterial isolates phylogenetically related to, but different from Mycobacterium simiae. J. Clin. Microbiol. 35:697-702.
392. Tortoli E, et al. 1995. Isolation of the newly described species Mycobacterium celatum from AIDS patients. J. Clin. Microbiol. 33:137-140.
393. Tsai T-F, et al. 2008. Tenosynovitis caused by Mycobacterium arupense in a patient with diabetes mellitus. Clin. Infect. Dis. 47:861-863.
394. Turenne CY, Wallace R, Jr, Behr MA. 2007. Mycobacterium avium in the postgenomic era. Clin. Microbiol. Rev. 20:205-229.
395. Udou T, Mizuguchi Y, Wallace RJ, Jr. 1987. Patterns and distribution of aminoglycoside-acetylating enzymes in rapidly growing mycobacteria. Am. Rev. Respir. Dis. 136:338-343.
396. Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW. 2006. Skin and soft tissue infections due to rapidly growing mycobacteria. Arch. Dermatol. 142:1287-1292.
397. Vadney FS, Hawkins JE. 1985. Evaluation of a simple method for growing Mycobacterium haemophilum. J. Clin. Microbiol. 28:884-885.
398. van der Heijden IM, et al. 1999. Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis. Rheumatology 38:547-553.
399. van Ingen J, et al. 2008. Clinical relevance of Mycobacterium szulgai in the Netherlands. Clin. Infect. Dis. 46:1200-1205.
400. van Ingen J, et al. 2009. Proposal to elevate Mycobacterium avium complex ITS sequevars MAC-Q to Mycobacterium vulneris sp. nov. Int. J. Syst. Evol. Microbiol. 59:2277-2282.
401. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. 2001. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature report. J. Infect. 43:163-168.
402. Villaneuva A, et al. 1997. Report on an outbreak of post-injection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin. Infect. Dis. 24:1147-1153.
403. Viveiros M, et al. 2002. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 2804-2810.
404. Vuorenmaa K, Ben Salah I, Barlogis V, Chambost H, Drancourt M. 2009. Mycobacterium colombiense and pseudotuberculous lymphadenopathy. Emerg. Infect. Dis. 15:619-620.
405. Wallace RJ, Jr. 2004. Infections due to nontuberculous mycobacteria, p 461-478. In Scheld WM, Whitley RJ, Marra CM (ed), Infections of the central nervous system, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
406. Wallace RJ, Jr, et al. 1990. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 34:65-70.
407. Wallace RJ, Jr, Brown BA, Griffith DE. 1991. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn. Microbiol. Infect. Dis. 16:215-221.
408. Wallace RJ, Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. 1996. Clarithromycin regimens for pulmonary Mycobacterium avium complex-the first 50 patients. Am. J. Respir. Crit. Care Med. 153:1766-1772.
409. Wallace RJ, Jr, Brown BA, Onyi G. 1991. Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillinclavulanic acid. Antimicrob. Agents Chemother. 35:773-775.
410. Wallace RJ, Jr, Brown BA, Onyi G. 1992. Skin, soft tissue, and bone infections due to Mycobacterium chelonae subspecies chelonae-importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166:405-412.
411. Wallace RJ, Jr, et al. 1991. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis. 163:598-603.
412. Wallace RJ, Jr, et al. 2005. Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense. J. Clin. Microbiol. 43: 5925-5935.
413. Wallace RJ, Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. 2002. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46:3164-3167.
414. Wallace RJ, Jr, et al. 2002. Clinical and laboratory features of Mycobacterium mageritense. J. Clin. Microbiol. 40:2930-2935.
415. Wallace RJ, Jr, et al. 2001. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother. 45:764-767.
416. Wallace RJ, Jr, et al. 2004. Clinical and laboratory features of Mycobacterium porcinum. J. Clin. Microbiol. 42:5689-5697.
417. Wallace RJ, Jr, Dalovisio JR, Pankey GA. 1980. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. Antimicrob. Agents Chemother. 16:611-614.
418. Wallace RJ, Jr, et al. 1994. Rifampin-resistant Mycobacterium kansasii. Clin. Infect. Dis. 18:736-743.
419. Wallace RJ, Jr, et al. 1985. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycosidemodifying enzyme assays. Am. Rev. Respir. Dis. 132:409-416.
420. Wallace RJ, Jr, Jones DB, Wiss K. 1981. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis. 3:898-904.
421. Wallace RJ, Jr, et al. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
422. Wallace RJ, Jr, Rosenbaum S. 1984. Pneumonia and vomiting: a fortuitous association? J. Respir. Dis. 5:88-94.
423. Wallace RJ, Jr, et al. 1993. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J. Clin. Microbiol. 31:3231-3239.
424. Wallace RJ, Jr, Steele LC, Labidi A, Silcox VA. 1989. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J. Infect. Dis. 160:281-288.
425. Wallace RJ, Jr, Swenson JM, Silcox VA. 1985. The rapidly growing mycobacteria: characterization and susceptibility testing. Antimicrob. Newsl. 2:85-92.
426. Wallace RJ, Jr, Swenson JM, Silcox VA, Bullen MG. 1985. Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J. Infect. Dis. 152:500-514.
427. Wallace RJ, Jr, Swenson JM, Silcox VA, Good RC. 1982. Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei. J. Clin. Microbiol. 16:1003-1006.
428. Wallace RJ, Jr, et al. 1983. Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis. 5:657-679.
429. Wallace RJ, Jr, Tanner D, Brennan PJ, Brown BA. 1993. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann. Int. Med. 119:482-486.
430. Wallace RJ, Jr, Wiss K, Bushby MB, Hollowell DC. 1982. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria. Rev. Infect. Dis. 4:326-331.
431. Wallace RJ, Jr, et al. 1998. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am. J. Respir. Crit. Care Med. 158:1235-1244.
432. Wallace RJ, Jr, et al. 2002. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J. Infect. Dis. 186:266-273.
433. Wallace RJ, Jr, et al. 2010. Abstr. Am. Thorac. Soc. Meet. 2010, abstr 502.
434. Wang F, et al. 2010. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob. Agents Chemother. 54:3776-3782.
435. Ward TT, et al. 1998. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 27:1278-1285.
436. Weycker D, Edelsberg J, Oster G, Tino G. 2005. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 12:205-209.
437. White DA, Kiehn TE, Bondoc AY, Massarella SA. 1999. Pulmonary nodule due to Mycobacterium haemophilum in an immunocompetent host. Am. J. Respir. Crit. Care Med. 160:1366-1368.
438. Whittier S, Hopfer RL, Knowles MR, Gilligan PH. 1993. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 31:861-864.
439. Williams DL, et al. 1998. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1853-1857.
440. Williams DL, Spring L, Harris E, Roche P, Gillis TP. 2000. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob. Agents Chemother. 44:1530-1537. (Erratum, 45: 647, 2001.)
441. Wilson DN, et al. 2008. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl. Acad. Sci. U. S. A. 105:13339-13344.
442. Wilson RW, et al. 2001. Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks, and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. Int. J. Syst. Evol. Microbiol. 51:1751-1764.
443. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. 2009. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg. Infect. Dis. 15:1556-1561.
444. Winthrop KL, et al. 2003. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. Am. J. Ophthalmol. 135:223-224.
445. Wirmer J, Westhof E. 2006. Molecular contacts between antibiotics and the 30S ribosomal particle. Methods Enzymol. 415:180-202.
446. Wiseman B, et al. 2010. Isonicotinic acid hydrazide conversion to isonicotinyl-NAD by catalase-peroxidases. J. Biol. Chem. 285:26662-26673.
447. Wolinsky E. 1979. Nontuberculous mycobacteria and associated diseases. Am. Rev. Respir. Dis. 119:107-159.
448. Wolter N, et al. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.
449. Woodruff HB, Foster JW. 1945. Microbiological aspects of penicillin. VII. Bacterial penicillinase. J. Bacteriol. 49:7-17.
450. Woods GL, et al. 2000. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 38:656-661.
451. Woods GL, et al. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676-1682.
452. Woods GL, et al. 2011. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
453. Woods GL, et al. 2003. Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes; approved standard. NCCLS document M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
454. Yajko DM, Kirihara J, Sanders C, Nassos P, Hadley WK. 1988. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob.Agents Chemother. 32:1392-1395.
455. Yang B, et al. 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42:621-628.
456. Yu JA, Pomerantz M, Bishop A, Weyant MJ, Mitchell JD. 2011. Lady Windermere revisited: treatment with thoracoscopic lobectomy/ segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur. J. Cardiothorac. Surg. 40:671-675.
457. Zaugg M, Salfinger M, Opravil M, Lüthy R. 1993. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin. Infect. Dis. 16:540-549.
458. Zeller V, et al. 2002. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin. Infect. Dis. 34:662-667.
459. Zenone T, et al. 1998. Nontuberculous mycobacterial tenosynovitis: report of two cases. Clin. Infect. Dis. 26:1467-1468.
460. Zhanel GG, et al. 2002. The ketolides: a critical review. Drugs 62:1771-1804.
461. Zhang P, Jiang G, Ding J, Zhou X, Gao W. 2010. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann. Thorac. Surg. 90:246-251.
462. Zhang Y, Telenti A. 2000. Genetics of drug resistance in Mycobacterium tuberculosis, p 235-254. In Hatfull GF, Jacobs WR, Jr (ed), Molecular genetics of mycobacteria. ASM Press, Washington, DC.
463. Zhang Y, Yew WW. 2009. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1320-1330.
464. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ruoss SJ. 2006. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 130:995-1002.